SRC and cancer: Mechanism wise, the inhibition of PITPNM3 suppressed the activation of Pyk2, FAK, and Src, and also impaired integrin clustering; indicating that PITPNM3 is a key player in cancer migration and invasion, therefore is a promising target in cancer therapy (C. He et al., 2014).